Jianyong Qi

Jianyong Qi

Auto-generated profile, based on publicly available information

Jianyong Qi

AMI Key Laboratory of Chinese Medicine in Guangzhou, Guangdong Province Academy of Chinese Medicine, Guangdong Province Hospital of Chinese Medicine, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou city,Guangdong province, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JYJuan Yu
Juan Yu
RCRenshan Chen
Renshan Chen
YTYafang Tan
Yafang Tan
JWJiashin Wu
Jiashin Wu
JQJianyong Qi
Jianyong Qi
WGWeiwang Gu
Weiwang Gu
Heart failure(HF) is a dangerous disease that affects millions of patients. Radix Salvia is widely used in Chinese clinics to treat heart diseases. Salvianolic acid B(SalB) is the major active component of Radix Salvia. This study investigated the mechanisms of action and effects of SalB on HF in an experimental mouse model of HF. We created a mouse model of HF by inducing pressure overload with transverse aortic constriction(TAC) surgery for 2 weeks and compared among 4 study groups: SHAM group (n = 10), TAC group (n = 9), TAC+MET group (metprolol, positive drug treatment, n = 9) and TAC+SalB group (SalB, 240 mg•kg-1•day-1, n = 9). Echocardiography was used to evaluate the dynamic changes in cardiac structure and function in vivo. Plasma brain natriuretic peptide (BNP) concentration was detected by Elisa method. In addition, H9C2 rat cardiomyocytes were cultured and Western blot were implemented to evaluate the phosphorylation of ERK1/2, AKT, and protein expression of GATA4. SalB significantly inhibited the phosphorylation of Thr202/Tyr204 sites of ERK1/2, but not Ser473 site of AKT, subsequently inhibited protein expression of GATA4 and plasma BNP(P < 0.001), and then inhibited HF at 2 weeks after TAC surgery. Our data provide a mechanism of inactivating the ERK1/2/GATA4 signaling pathway for SalB inhibition of the TAC-induced HF.

1 January 2012 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
LWLei Wang
Lei Wang
MZMinzhou Zhang
Minzhou Zhang
LGLiheng Guo
Liheng Guo
JQJianyong Qi
Jianyong Qi
HLHaiming Luo
Haiming Luo
JWJiashin Wu
Jiashin Wu
Objective. To determine the impact of an integrative medicine clinical pathways (CPs) on the length of in-hospital stay and on outcomes for patients with acute myocardial infarction (AMI).Methods. A multicenter nonrandomized controlled trial enrolling 197 consecutive patients with AMI at eight urban TCM hospitals was conducted between 1 January 2010 and 31 October 2010. These patients were enrolled in the interventional group after the CPs had been implemented. The control group included 405 patients with AMI from eight hospitals; these patients were treated between 1 January 2008 and 31 December 2009, before the CPs were implemented. Outcome measures were the length of hospital stay costs of medical care, and major cardiovascular events (MACEs) during hospitalization.Results. Compared with the control group, the patients in intervention group had a shorter length of hospital stay (9.2±4.2days versus12.7±8.6days,P<0.05), and reduced healthcare costs in hospital (46365.7±18266.9versus52866.0±35404.4,P<0.05). There were statistically significant differences in MACE between the two groups during the hospitalization period (2.5% versus 6.9%,P=0.03).Conclusion. These data suggest that the development and implementation of the clinical pathways based in Integrative Medicine could further improve quality of care and outcome for patients with AMI.

1 January 2014 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JQJianyong Qi
Jianyong Qi
QLQin Liu
Qin Liu
KGKaizheng Gong
Kaizheng Gong
JYJuan Yu
Juan Yu
LWLei Wang
Lei Wang
MZMinzhou Zhang
Minzhou Zhang
Background. Cardiac hypertrophy occurs in many cardiovascular diseases. Apocynum tablet (AT), a traditional Chinese medicine, has been widely used in China to treat patients with hypertension. However, the underlying molecular mechanisms of AT on the hypertension‐induced cardiac hypertrophy remain elusive. The current study evaluated the effect and mechanisms of AT on cardiac hypertrophy. Methods. We created a mouse model of cardiac hypertrophy by inducing pressure overload with surgery of transverse aortic constriction (TAC) and then explored the effect of AT on the development of cardiac hypertrophy using 46 mice in 4 study groups (combinations of AT and TAC). In addition, we evaluated the signaling pathway of phosphorylation of ERK1/2, AKT, and protein expression of GATA4 in the cardioprotective effects of AT using Western blot. Results. AT inhibited the phosphorylation of Thr202/Tyr204 sites of ERK1/2, Ser473 site of AKT, and protein expression of GATA4 and significantly inhibited cardiac hypertrophy and cardiac fibrosis at 2 weeks after TAC surgery (P < 0.05). Conclusions. We experimentally demonstrated that AT inhibits cardiac hypertrophy via suppressing phosphorylation of ERK1/2 and AKT.

1 September 2013 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JQJianyong Qi
Jianyong Qi
JYJuan Yu
Juan Yu
LWLei Wang
Lei Wang
LGLiheng Guo
Liheng Guo
SMShiyu Ma
Shiyu Ma
MZMinzhou Zhang
Minzhou Zhang
Myocardial ischemia/reperfusion (I/R) can induce lethal ventricular arrhythmia and myocardial infarction. One of the clinical strategies for managing patients with high risk of myocardial I/R is to prevent the occurrence of arrhythmias and limit the size of infarction following a coronary episode. Tongguan Capsule (TGC) is one of the popular herbal remedies in treating coronary artery disease in the clinics of Chinese medicine. However, the potential roles and mechanisms of TGC in reducing I/R injury are still unclear. The present study statistically assessed the effectiveness of TGC in reducing I/R injury by comparing the infarct size (IS), risk region (RR), and arrhythmia (in electrocardiogram) among four groups of surgically created mice models of myocardial I/R: SHAM, I/R, VER (I/R with verapamil 20 mg/kg pretreatment), and TGC (I/R with TGC 5 g/kg/d pretreatment). We found that IS was significantly smaller in the TGC and VER groups than I/R group, and the incidence of arrhythmias was reduced in the TGC group compared with I/R group, although there were no differences in RR among the four groups. We conclude that TGC is effective in reducing I/R injury in mice. These results provided an experimental basis for clinical application of TGC in reducing I/R injury.

20 February 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JQJianyong Qi
Jianyong Qi
JYJuan Yu
Juan Yu
MZMinzhou Zhang
Minzhou Zhang
DXDaoyin Xie
Daoyin Xie
FPFei Pei
Fei Pei
JWJiashin Wu
Jiashin Wu

1 October 2014 in International Journal of Cardiology
Verified
Journal Article
Closed access
JQJianyong Qi
Jianyong Qi
YRYi Ren
Yi Ren
LWLei Wang
Lei Wang
LGLiheng Guo
Liheng Guo
JWJiashin Wu
Jiashin Wu
MZMinzhou Zhang
Minzhou Zhang